BRAF and melanoma: BRAF V600E Mutation in Melanoma: The BRAF V600E mutation in melanoma is a predictive biomarker for response to BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK inhibitors (e.g., trametinib and cobimetinib) [407].